Acceleron Pharma (XLRN) Tops Q3 EPS by 3c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q3 EPS by 3c, Revenues Miss

Acceleron Reports Third Quarter 2018 Operating and Financial Results

October 30, 2018 4:05 PM EDT

MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes (MDS) and beta-thalassemia, respectively, are expected to be presented at the 60th American Society of Hematology (ASH) Annual Meeting

COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has been initiated

Part 1 results from the ACE-083 Phase 2 trial in facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) were presented at the World Muscle Society Annual Meeting

Pulmonary Arterial Hypertension (PAH) R&D Deep Dive Event scheduled for Friday, November 16th in... More